The present invention in general relates to medical devices and systems, and in particular to vacuum dressings with a guide tube for implantable medical devices that reduces the complications associated therewith.
Intravenous catheters act as an attachment point for microorganisms, leading to biofilm formation and infection at the site of insertion or along the surface of the device. Infection of the catheter hub and catheter-related bloodstream infections are major complications for patients with indwelling catheters (e.g., Safdar and Maki, Intensive Care Med. 2004 January; 30(1):62-7; Saint et al., Infect Control Hosp Epidemiol. 2000 June; 21(6):375-80).
Prior attempts at controlling catheter-related infection are directed to sterilization techniques such as by topical or fluidic antibacterials applied to the insertion site or integrated into the catheter itself. The antimicrobial lytic activity of C1-C8 alcohols is well known. Isopropyl alcohol at a concentration of 60-70% is widely used as an antimicrobial agent for sanitization of surfaces and skin. A concentration of 10% ethyl alcohol inhibits the growth of most microorganisms, while concentrations of 40% and higher are generally considered bactericidal (Sissons et al., Archives of Oral Biology, Vol. 41, 1, JN 1996; 27-34).
Catheters and other in-dwelling medical devices can be kept in place for as little as a few seconds for drainage or delivery of a substance. Besides catheters, other such devices illustratively include cannulas, lines for left ventricular assist devices (LVADs) chest tubes, and the like. It is increasingly common, however, for such devices and specifically peripherally inserted central catheters (PICC), skeletal guide wires, cardiac assist device lines, to be kept in place for weeks, months, or even years. The increased time in which such devices are maintained across the skin increases the likelihood of incision cleft related infection around such devices.
Another common implantable device that breaks the skin and may be a source of infection are blood pumps that may be surgically implanted in, or adjacent to the cardiovascular system to augment the pumping action of the heart. The blood pump is sometimes referred to as a mechanical auxiliary ventricle assist device, dynamic aortic patch, balloon pump, mechanical circulatory assist device, or a total mechanical heart. Alternatively, the blood pump can be inserted endovascularly. Typically, the blood pump systems include a driveline that serves as a power and/or signal conduit between the blood pump internal to the patient and a controller/console external to the patient. Additional external medical devices may illustratively include implantable pumps such as insulin pumps and colostomy bags.
Percutaneous access devices (PAD) have been introduced that serve as semi-permanent or extended entry points for the aforementioned catheters and implantable and externally worn medical devices. For example, a percutaneous access device (PAD) may be surgically implanted in the body at the location in the skin where the driveline penetrates the skin to provide a through-the-skin coupling for connecting the supply tube to an extra-corporeal fluid pressure source. In a further example, electrical leads from electrodes implanted in the myocardium are likewise brought out through the skin by means of the PAD. Percutaneous access devices may also illustratively be used for other devices including peritoneal dialysis catheters, Steinman pin, Kirschner wires, and chronic indwelling venous access catheters that require skin penetration. More generally, medical appliances which are implanted so as to cross the skin surface and therefore violate the “barrier function” of the skin, may also illustratively be used for other medical purposes including peritoneal dialysis catheters and, chronic indwelling venous access catheters, neurologic prostheses, osseointegrated prostheses, drug pumps, and other treatments that require skin penetration.
The use of percutaneous access devices inhibits penetration or complications due to the presence of an agent in a subject. As used herein an “agent” is illustratively: an infectious agent such as bacteria, virus, fungus, other organism; or foreign material. Illustrative examples of foreign material include: bandage; soil; water, saliva, urine, or other fluid; feces; chemicals; or other matter known in the art. Illustrative examples of infectious agents that are prevented from penetrating or produce complications include P. aeruginosa, E. cloacae; E. faecalis; C. albicans; K pneumonia; E. coli; S. aureus; or other infectious agents. As used herein, the term “subject” refers to a human or non-human animal, optionally a mammal including a human, non-primate such as cows, pigs, horses, goats, sheep, cats, dogs, avian species and rodents; and a non-human primate such as monkeys, chimpanzees, and apes; and a human, also denoted specifically as a “human subject”.
A draw force is typically applied to a PAD to counteract fluid collection or flow along a percutaneous instrument tissue interface. It is common for fluid to develop in the space surrounding a percutaneous instrument often beginning immediately after insertion. The presence of this fluid allows migration, flow, or other penetration of agents normally excluded by the intact skin to areas below the skin. The penetration by these agents may lead to development of infectious disease, inflammation at the site of insertion, or other unwanted complications. A draw force that is applied is vacuum or hydrodynamic draw through capillary action. A draw force illustratively prevents fluid from moving along an interface between tissue and the embedded catheter or other instrument. The negative pressure of the draw allows the natural pressures of biological material or other atmospheric pressure to move unwanted material away from the areas at or below the site of insertion.
The surface of the driveline, or of the PAD used in cardiac assist systems may have characteristics which promote the formation of a natural biologic seal between the skin and the device to form a barrier to microbial invasion into the body at the skin penetration site. However, a common problem associated with implantation of a percutaneous access device (PAD) is skin regeneration about the periphery of the device to form an immunoprotective seal against infection. New cell growth and maintenance is typically frustrated by the considerable mechanical forces exerted on the interfacial layer of cells. In order to facilitate skin regeneration about the exterior of a PAD, subject cells are often harvested and grown in culture onto PAD surfaces for several days prior to implantation in order to allow an interfacial cell layer to colonize PAD surfaces in advance of implantation. Unfortunately, cell culturing has met with limited acceptance owing to the need for a cell harvesting surgical procedure preceding the implantation procedure. Additionally, maintaining tissue culture integrity is also a complex and time-consuming task.
As an alternative to cell culturing on a percutaneous access device, vacuum assisted wound treatment about a percutaneous access device has been attempted. While DACRON® based random felt meshes have been used to promote cell regrowth in the vicinity of a wound, such felts have uncontrolled pore sizes that can harbor bacterial growth pockets.
U.S. Pat. No. 7,704,225 solves many of these aforementioned problems by providing cell channeling contours, porous biodegradable polymers and the application of vacuum to promote cellular growth towards the surface the neck of a PAD. The facilitating of rapid cellular colonization of a PAD neck allows the subject to act as their own cell culture facility, and as such affords more rapid stabilization of the PAD, and lower incidence of separation and infection. Coating substances thereon illustratively include cell growth scaffolding matrices as detailed in U.S. Pat. Nos. 5,874,500; 6,056,970; and 6,656,496; and Norman et al. Tissue Eng. March 2005, 11(3-4) pp. 375-386.
An outer sleeve of a PAD functions to segregate or deliver vacuum draw pressure to an inner sleeve. The outer sleeve optionally circumferentially and longitudinally covers an inner sleeve. This configuration optionally shields the inner sleeve from epidermal bacterial or other agents upon insertion. An outer sleeve is optionally tapered at one or both ends. Tapering at a distal end (the end nearest the internal end of the catheter during use) provides improved insertion of the instrument into the skin of a subject. A taper may form a smooth interaction with the catheter at the outer sleeve distal end or a ridge is optionally present at or near the site of device interaction with the catheter.
A vacuum source can be any source operable for creating negative pressure in or around the device. A vacuum source is optionally a passive vacuum such as a vacuum tube or bottle, or an active vacuum source illustratively a mechanical pump, a syringe, or other vacuum source. A hydrodynamic draw agent is provided that draws fluid from the tissue surrounding through the sleeve via the conduit. A hydrodynamic draw source illustratively includes a super absorbent polymer such as sodium polyacrylate, polyacrylamide copolymer, ethylene maleic anhydride copolymer, cross-linked carboxymethylcellulose, polyvinyl alcohol copolymers, cross-linked polyethylene oxide, and starch grafted copolymer of polyacrylonitrile; high osmotic pressure compositions, such as water soluble salts; and capillary flow draw agents such as dry silica, or other dry hydrophilic powders such cellulosic material. It is noted that recently a diaper filler in the form of a polyacrylic acid as a superabsorbent polymer and a bactericidal skin wash chlorhexidine has been used to draw fluid from the tissue surrounding the sleeve via the conduit. However, this approach to fluid draw has limited and exponentially decaying moisture draw.
The modular external interface 200 is secured and sealed to an outer layer of a patient's skin with a medical dressing. In a specific embodiment the medical dressing is a preform patterned and shaped to conform to the exterior of the modular external interface 200. In a specific embodiment the medical dressing preform may be in two halves (212, 214) that overlap. In a specific embodiment the medical dressing preform may be transparent. In a specific embodiment the medical dressing preform may be made of Tegaderm™ manufactured by Minnesota Mining and Manufacturing Company.
Despite the advances in PAD design and the securement of PAD to a subject's skin there continues to be a problem of disrupting the formation and maintaining of skin layers about the PAD with respect to flexible or pliable drivelines during the healing process. In addition, while vacuum pumps, capillary draw, and hydrodynamic draw have been used reduce the pressure on the insertion site and thereby dry the insertion site to stimulate granulation that will mechanically stabilize the appliance and reduce the prospect of infection; infection at the site of device insertion used with pliable and flexible drivelines continues to occur as the seal between the layers of skin and the bendable driveline tends to either not fully form or fails as the driveline flexes at the insertion site. Furthermore, there continues to be a need to adjust pressure to preclude skin prolapse around a catheter or other temporarily or in-dwelling medical device.
There is a continuing need for improved dressings for percutaneous access devices that encourage and expedite nascent layers of skin that are being formed during the healing process, as well as maintaining an infection preventive seal with evacuation of fluids that support bacteria that lead to infection around percutaneous access devices
A vacuum access therapeutic (VAT) is provided to engage a guide tube extending above and out of an epidermal layer. The VAT includes a central dressing adapted to overlay the epidermal layer to surround a guide tube, an outer dressing surrounding the central dressing, and a locating ring intermediate between the central dressing and the outer dressing. A connector coupling the vacuum access therapeutic to a vacuum source, the connector in gaseous communication with the central dressing and the guide tube.
A process is provided for stabilizing an implanted medical device having a guide tube therearound at a situs emerging from patient epidermis. The process includes attaching a vacuum access therapeutic as described above onto the epidermis at the situs, and coupling the vacuum access therapeutic to a vacuum source. Subsequently, a vacuum is applied in a volume between the guide tube and the implanted medical device.
The subject matter that is regarded as the invention is particularly pointed out and distinctly claimed in the claims at the conclusion of the specification. The foregoing and other objects, features, and advantages of the invention are apparent from the following detailed description taken in conjunction with the accompanying drawings in which like reference numerals refer to like parts throughout the several views, and wherein:
Embodiments of the invention provide vacuum dressings with a guide tube for implantable medical devices that inhibits infection and in some inventive embodiments associated with in-dwelling devices encourages healing of the incision around the device. Inventive vacuum dressings mitigate pooling of fluids that harbor bacteria from between the outer diameter of an inserted implantable medical device and the inner diameter of a guide tube and also in the cylindrical gap, between the outer diameter of an inserted implantable medical device and the inner wall of the subcutaneous tunnel, which remains in fluid communication with skin microflora. Implantable medical devices may also illustratively include a variety of catheters, such as venous access, peritoneal dialysis, and other indwelling venous access catheters that require skin penetration; cannulas; Steinman pins; Kirschner wires; and cardiac assist device lines.
Previous efforts have concentrated on complete removal of moisture or humidity from wound areas, however, according to the present invention, it is noted that in some instances, a level of moisture is required to allow fibroblasts to actively attach to an implanted device or tube, or to a localized fibroblast attachment feature, surrounding such a device and to promote the establishment of intact biological barrier function of the stratum corneum layer of skin. According to the present invention, it is also noted that moisture and pressure levels may be needed to change as the wound healing process progresses through different stages. According to the present invention, it is further noted that pressure levels may require adjustment to preclude skin prolapse around an implanted device. In specific inventive embodiments, a vacuum applies an intermittent negative pressure or oscillating negative pressure or negative pressure modulated based on real-time measurements of relevant physiologic parameters such as tissue oxygenation, local pH, moisture egressing from the subcutaneous tunnel, and the like. This has been found to be surprisingly effective in preventing tissue prolapse, telangiectasias, and sealing of distal subcutaneous pockets that can harbor fluids and microbes. The magnitude of the negative pressure is optionally adjustable, constant, or variable. Intermittent vacuum can be applied for periods of 1 millisecond to 12 hours with rest periods therebetween that independently vary from 1 millisecond to 12 hours. The rest periods are either a venting to ambient room pressure or a cessation of active vacuum draw to allow a slow increase in pressure towards ambient pressure through gas or fluid leakage into the central dressing. It is appreciated that a comparatively weak vacuum draw pulsed rapidly on and off on the order of 1 millisecond to 10 seconds simulates the behavior of hydrodynamic draw without the need for routine monitoring and changing of materials. Embodiments of the inventive guide tube are intended to be changed every 1 to 7 days as needed. Embodiments of the inventive guide tube have the following characteristics:
i) Multiple channels, grooves, and/or open cell interconnected channels capable of conducting vacuum from the exterior vacuum dressing, along the length of the subcutaneous tunnel, to remain in fluid communication with a fibroblast adhesion feature.
ii) Material properties such that the multiple channels identified in i) above resist collapse under the influence of the vacuum applied to the system.
iii) Material properties such that, during the act of removal of the guide tube, the external surface of the guide tube is non-adherent and resists adhesive interference/abrasion with epidermal cells which have migrated from the external epidermis along the walls of the subcutaneous tunnel. This process of epidermal downward migration into the subcutaneous tunnel is referred to as “Marsupialization”.
iv) Geometric properties such that, in the act of removal of the guide tube (“peel away functionality”), heavy disruptive forces delivered to the healing fibroblasts and epidermal cells are minimized Such geometries may include, but are not limited to, pre-formed perforations, pull-strips, circumferential segmentation into multiple parallel or non-parallel longitudinal ribbon-like or thread-like segments which anticipate the “peel-away” functionality, or a spiral configuration allowing a spiral-on application procedure and a spiral-off removal procedure. The segments of the guide tube can optionally include a stiffening element.
v) Material and geometric properties of the guide tube which are compatible with an insertion tool which aid in placement of the vacuum guide sleeve within the gap space between the walls of the subcutaneous tunnel and the therapeutic catheter.
Referring now to the figures,
When a fibroblast adhesion feature is available (e.g., Dacron Cuff, nano textured polycarbonate PAD, expanded perfluoropolymers, etc.), the role of the non-adhering guidance tube during the initial post-implant wound healing phase is to:
a) Provide fluid communication of negative pressure wound therapy to the gap between the therapeutic catheter and the wall of the subcutaneous tunnel so as to reduce bioburden accumulation within the subcutaneous tunnel.
b) Provide fluid communication of negative pressure wound therapy to the Fibroblast adhesion feature so as to reduce bioburden associated with the fibroblast adhesion feature and to encourage fibroblast infiltration and adhesion of the fibroblast adhesion feature.
c) During dressing changes that include changing of the non-adhering guidance tube, provide for gentle mechanical debridement of the gap between the therapeutic catheter and the wall of the subcutaneous tunnel while avoiding injury to migrating epithelial cells as they down migrate along the walls of the subcutaneous tunnel to reach the fibroblast adhesion feature (a process referred to as “marsupialization”).
When a fibroblast adhesion feature (e.g., Dacron cuff, nano textured polycarbonate PAD, etc) is available, the role of the non-adhering vacuum guidance tube during the post-implant maintenance phase is to:
a) Provide fluid communication of negative pressure wound therapy to the gap between the therapeutic catheter and the wall of the subcutaneous tunnel so as to reduce bioburden accumulation within the subcutaneous tunnel.
b) During dressing changes that include changing of the non-adhering guidance tube, provide for gentle mechanical debridement of the gap between the therapeutic catheter and the wall of the subcutaneous tunnel while avoiding injury to migrating epithelial cells as they down migrate along the walls of the subcutaneous tunnel to reach the fibroblast adhesion feature (a process referred to as “marsupialization”)
When a fibroblast adhesion feature (e.g. Dacron cuff, nano textured polycarbonate PAD, etc) is not integrated into the therapeutic catheter (as would be the case with IV catheters, intraarterial catheters, Steinman pins, etc., the role of the short non-adhering Vacuum guidance tube during the post-implant phase is to provide fluid communication of negative pressure wound therapy to create a hydrostatic gradient to the gap between the therapeutic catheter and the wall of the subcutaneous tunnel so as to reduce bioburden accumulation within the subcutaneous tunnel.
It is appreciated that as a therapeutic catheter 314 is passed through the segmented orifice 328 opening, the petals will bend from the plane of the epidermis to follow the outer wall of the therapeutic catheter. The portions of the petals remaining undisturbed in the plane of the epidermis will remain in immediate adjacency. However, the portions of the petals which have bent to follow the outer wall of the therapeutic catheter 314 will spread apart from their adjacent neighboring petals. This spreading will allow fluid communication of the vacuum to portions of the wall of the subcutaneous tunnel. The inventive alternate pattern will allow precise accommodation of the central dressing 326 to variations in the outer diameter of the therapeutic catheter 314.
Patent documents and publications mentioned in the specification are indicative of the levels of those skilled in the art to which the invention pertains. These documents and publications are incorporated herein by reference to the same extent as if each individual document or publication was specifically and individually incorporated herein by reference.
The foregoing description is illustrative of particular embodiments of the invention, but is not meant to be a limitation upon the practice thereof. The following claims, including all equivalents thereof, are intended to define the scope of the invention.
This application claims priority benefit of U.S. Provisional Application Ser. No. 62/935,683 filed 15 Nov. 2019, the contents of which are hereby incorporated by reference.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/060668 | 11/16/2020 | WO |
Number | Date | Country | |
---|---|---|---|
62935683 | Nov 2019 | US |